Xu Lab
Lu S, Yin Z, Wu L, Sun Y, Chen J, Wu LMN, Oblinger JL, Blake DC, Landegger LD, Seist R, Ho W, Xiu B, Jones AP, Muzikansky A, Stankovic KM, Plotkin SR, Chang LS, Xu L
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model.
bioRxiv. 2024;:ePub - PMID: 39763968 - PMCID: PMC11703165 - DOI: 10.1101/2024.12.29.630658
LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO
Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma.
Oncology. 2024;:1-8 - PMID: 39427654 - DOI: 10.1159/000541250
Sun Y, Yin Z, Li S, Wu L, Zhang Y, Zhao Y, Gomes Dos Santos IL, Subudhi S, Lei P, Muzikansky A, Yuan Z, Rueda BR, Jain RK, Xu L
Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.
Br J Cancer. 2024;131(10):1683-1693 - PMID: 39369055 - PMCID: PMC11554678 - DOI: 10.1038/s41416-024-02863-9
Datta M, Via LE, Dartois V, Xu L, Barry CE, Jain RK
Leveraging insights from cancer to improve tuberculosis therapy.
Trends Mol Med. 2024;31(1):11-20 - PMID: 39142973 - PMCID: PMC11717643 - DOI: 10.1016/j.molmed.2024.07.011
Lu S, Yin Z, Chen J, Wu L, Sun Y, Gao X, Huang P, Jordan JT, Plotkin SR, Xu L
Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.
Cancers (Basel). 2024;16(11):ePub - PMID: 38893082 - PMCID: PMC11171041 - DOI: 10.3390/cancers16111961
Datta M, Via LE, Dartois V, Weiner DM, Zimmerman M, Kaya F, Walker AM, Fleegle JD, Raplee ID, McNinch C, Zarodniuk M, Kamoun WS, Yue C, Kumar AS, Subudhi S, Xu L, Barry CE, Jain RK
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits.
Proc Natl Acad Sci U S A. 2024;121(14):e2321336121 - PMID: 38530888 - PMCID: PMC10998582 - DOI: 10.1073/pnas.2321336121
Datta M, Kennedy M, Siri S, Via LE, Baish JW, Xu L, Dartois V, Barry CE, Jain RK
Mathematical model of oxygen, nutrient, and drug transport in Tuberculosis Granulomas.
PLoS Comput Biol. 2024;20(2):e1011847 - PMID: 38335224 - PMCID: PMC10883541 - DOI: 10.1371/journal.pcbi.1011847
Zhao F, Chen Y, Li SW, Zhang J, Zhang S, Zhao XB, Yang ZJ, Wang B, He QY, Wang LM, Xu L, Liu PN
Novel patient-derived xenograft and cell line models for therapeutic screening in NF2-associated schwannoma.
J Pathol. 2022;257(5):620-634 - PMID: 35394061 - DOI: 10.1002/path.5908
Ho WW, Gomes-Santos IL, Aoki S, Datta M, Kawaguchi K, Talele NP, Roberge S, Ren J, Liu H, Chen IX, Andersson P, Chatterjee S, Kumar AS, Amoozgar Z, Zhang Q, Huang P, Ng MR, Chauhan VP, Xu L, Duda DG, Clark JW, Pittet MJ, Fukumura D, Jain RK
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
Proc Natl Acad Sci U S A. 2021;118(45):ePub - PMID: 34725151 - PMCID: PMC8609309 - DOI: 10.1073/pnas.2105323118
Amoozgar Z, Kloepper J, Ren J, Tay RE, Kazer SW, Kiner E, Krishnan S, Posada JM, Ghosh M, Mamessier E, Wong C, Ferraro GB, Batista A, Wang N, Badeaux M, Roberge S, Xu L, Huang P, Shalek AK, Fukumura D, Kim HJ, Jain RK
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
Nat Commun. 2021;12(1):2582 - PMID: 33976133 - PMCID: PMC8113440 - DOI: 10.1038/s41467-021-22885-8
Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, Ng MR, Chen JW, Zhang N, Zhao Y, Gao X, Fujita T, Roberge S, Huang P, Jain RK, Plotkin SR, Stankovic KM, Xu L
A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.
Nat Protoc. 2019;14(2):541-555 - PMID: 30617350 - PMCID: PMC6571021 - DOI: 10.1038/s41596-018-0105-7
Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, Yeku O, Del Carmen MG, Spriggs DR, Jain RK, Xu L
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Proc Natl Acad Sci U S A. 2019;116(6):2210-2219 - PMID: 30659155 - PMCID: PMC6369817 - DOI: 10.1073/pnas.1818357116
Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, Zhao F, Zhao Y, Zhang Y, Zhang J, Fujita T, Stemmer-Rachamimov A, Ferraro GB, Liu H, Muzikansky A, Plotkin SR, Stankovic KM, Jain RK, Xu L
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Proc Natl Acad Sci U S A. 2018;115(9):E2077-E2084 - PMID: 29440379 - PMCID: PMC5834719 - DOI: 10.1073/pnas.1719966115
Askoxylakis V, Badeaux M, Roberge S, Batista A, Kirkpatrick N, Snuderl M, Amoozgar Z, Seano G, Ferraro GB, Chatterjee S, Xu L, Fukumura D, Duda DG, Jain RK
A cerebellar window for intravital imaging of normal and disease states in mice.
Nat Protoc. 2017;12(11):2251-2262 - PMID: 28981123 - PMCID: PMC5918134 - DOI: 10.1038/nprot.2017.101
Zhang N, Gao X, Zhao Y, Datta M, Liu P, Xu L
Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma.
J Rare Dis Res Treat. 2017;1(2):51-55 - PMID: 28191549 - PMCID: PMC5300073
Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Proc Natl Acad Sci U S A. 2016;113(16):4470-5 - PMID: 27044097 - PMCID: PMC4843449 - DOI: 10.1073/pnas.1525349113
Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Proc Natl Acad Sci U S A. 2016;113(16):4476-81 - PMID: 27044098 - PMCID: PMC4843473 - DOI: 10.1073/pnas.1525360113
Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.
Cell. 2013;152(5):1065-76 - PMID: 23452854 - PMCID: PMC3587980 - DOI: 10.1016/j.cell.2013.01.036
Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, Ancukiewicz M, Boucher Y, Jain RK, Xu L
TGF-? blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.
Proc Natl Acad Sci U S A. 2012;109(41):16618-23 - PMID: 22996328 - PMCID: PMC3478596 - DOI: 10.1073/pnas.1117610109
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK
Normalization of the vasculature for treatment of cancer and other diseases.
Physiol Rev. 2011;91(3):1071-121 - PMID: 21742796 - PMCID: PMC3258432 - DOI: 10.1152/physrev.00038.2010
Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
J Neurooncol. 2011;103(2):325-32 - PMID: 20821342 - PMCID: PMC4090923 - DOI: 10.1007/s11060-010-0390-7
Liao S, Liu J, Lin P, Shi T, Jain RK, Xu L
TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models.
Clin Cancer Res. 2011;17(6):1415-24 - PMID: 21278244 - PMCID: PMC3060297 - DOI: 10.1158/1078-0432.CCR-10-2429
Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
Clin Cancer Res. 2011;17(8):2074-80 - PMID: 21349998 - PMCID: PMC3079023 - DOI: 10.1158/1078-0432.CCR-10-2636
Liu J, Liao S, Huang Y, Samuel R, Shi T, Naxerova K, Huang P, Kamoun W, Jain RK, Fukumura D, Xu L
PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.
Clin Cancer Res. 2011;17(11):3638-48 - PMID: 21459800 - PMCID: PMC3107920 - DOI: 10.1158/1078-0432.CCR-10-2456
Xu L, Czito BG, Willett CG
Epigenetic markers in rectal cancer.
Clin Cancer Res. 2010;16(10):2699-701 - PMID: 20460492 - DOI: 10.1158/1078-0432.CCR-10-0559
Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
Cancer Res. 2009;69(20):7905-10 - PMID: 19826039 - PMCID: PMC2859041 - DOI: 10.1158/0008-5472.CAN-09-2099
Willett CG, Duda DG, Xu L, diTomaso E, Boucher Y, Czito B, Ancukiewicz M, Clark J, Carroll M, Lauwers G, Jain RK
Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC).
J Clin Oncol. 2008;26(15_suppl):4096 - PMID: 27949464
Kashiwagi S, Tsukada K, Xu L, Miyazaki J, Kozin SV, Tyrrell JA, Sessa WC, Gerweck LE, Jain RK, Fukumura D
Perivascular nitric oxide gradients normalize tumor vasculature.
Nat Med. 2008;14(3):255-7 - PMID: 18278052 - DOI: 10.1038/nm1730
Xu L, Jain RK
Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma.
Mol Cancer Res. 2007;5(9):873-80 - PMID: 17704140 - DOI: 10.1158/1541-7786.MCR-06-0141
Lawenda BD, Smith DE, Xu L, Niemierko A, Silverstein JR, Boucher Y, Kashiwagi S, Held KD, Jain RK, Loeffler JS, Eisenberg DM, Blumberg JB
Do the dietary supplements epigallocatechin gallate or vitamin e cause a radiomodifying response on tumors in vivo? A pilot study with murine breast carcinoma.
J Soc Integr Oncol. 2007;5(1):11-7 - PMID: 17309809 - DOI: 10.2310/7200.2006.033
Jain RK, Xu L
alphaPlGF: a new kid on the antiangiogenesis block.
Cell. 2007;131(3):443-5 - PMID: 17981110 - DOI: 10.1016/j.cell.2007.10.023
Hagendoorn J, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP, Xu L, Kucherlapati R, Jain RK
Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis.
Cancer Res. 2006;66(7):3360-4 - PMID: 16585153 - DOI: 10.1158/0008-5472.CAN-05-2655
Xu L, Cochran DM, Tong RT, Winkler F, Kashiwagi S, Jain RK, Fukumura D
Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models.
Cancer Res. 2006;66(8):3971-7 - PMID: 16618713 - DOI: 10.1158/0008-5472.CAN-04-3085
Kashiwagi S, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL, Buerk DG, Munn LL, Jain RK, Fukumura D
NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels.
J Clin Invest. 2005;115(7):1816-27 - PMID: 15951843 - PMCID: PMC1143589 - DOI: 10.1172/JCI24015
Xu L, Tong R, Cochran DM, Jain RK
Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
Cancer Res. 2005;65(13):5711-9 - PMID: 15994946 - DOI: 10.1158/0008-5472.CAN-04-4313
Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
Cancer Cell. 2004;6(6):553-63 - PMID: 15607960 - DOI: 10.1016/j.ccr.2004.10.011
Xu L, Pathak PS, Fukumura D
Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells.
Clin Cancer Res. 2004;10(2):701-7 - PMID: 14760093 - DOI: 10.1158/1078-0432.ccr-0953-03
Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E, Barnett GH, Jain RK
The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis.
Nature. 2004;428(6980):328-32 - PMID: 15029197 - DOI: 10.1038/nature02329
Bockhorn M, Tsuzuki Y, Xu L, Frilling A, Broelsch CE, Fukumura D
Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
Clin Cancer Res. 2003;9(11):4221-6 - PMID: 14519649
Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K, Garkavtsev I, Jain RK
Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis.
Circ Res. 2003;93(9):e88-97 - PMID: 14525808 - PMCID: PMC2755542 - DOI: 10.1161/01.RES.0000099243.20096.FA
Herrera CA, Xu L, Bucana CD, Silva el VG, Hess KR, Gershenson DM, Fidler IJ
Expression of metastasis-related genes in human epithelial ovarian tumors.
Int J Oncol. 2002;20(1):5-13 - PMID: 11743636
Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK
Tumour biology: herceptin acts as an anti-angiogenic cocktail.
Nature. 2002;416(6878):279-80 - PMID: 11907566 - DOI: 10.1038/416279b
Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK
Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.
Cancer Res. 2001;61(16):6020-4 - PMID: 11507045
43